There’s a significant need for new pain relievers that don’t pose the risk of addiction, and Cara Therapeutics (NASDAQ:CARA) has multiple studies with data on tap that could prove it has developed a better approach to addressing pain than existing medication.
A flurry of activity
The company is working on CR845, a drug that tackles pain differently than opioids like oxycodone and fentanyl.
